A case series of patients with pustular psoriasis indicated a lack of standardized treatment and continued health care utilization, in which men were at greater risk of an emergency department or hospital encounter.
There remains no standardized treatment for generalized pustular psoriasis (GPP), with continued health care utilization experienced by these patient populations, according to study findings published recently in JAMA Dermatology.
As an orphan disease characterized by the rapid appearance of sterile pustules and generalized erythema, GPP has been indicated to have genetic risk factors different from other types of psoriasis. Moreover, the researchers note that patients with the rare, chronic disease are often systemically ill and may experience severe organ dysfunction, and rarely death.
With limited information on the pathophysiology of GPP, they conducted a retrospective longitudinal case series to examine the clinical characteristics, natural disease course, treatments, and health care utilization of affected US patients.
The study included 95 adult patients with GPP (mean [SD] age, 50.3 [16.1] years; 70.5% female) who met the European Rare and Severe Psoriasis Expert Network consensus definition for the disease and were treated at 20 US academic dermatology practices between January 1, 2007, and December 31, 2018.
Regarding initial presentation of disease, 35 patients (36.8%) presented during an inpatient admission, 9 (9.5%) in the emergency department (ED), and 51 (53.7%) during an outpatient or ambulatory dermatology office visit. Of the 57 patients who had no prior history of GPP, 29 (50%) were inpatient admissions or ED encounters.
The presence of pustules on the trunk and extremities was reported in a majority of patients, with several other symptoms, as well as comorbidities, associated with GPP:
The most common comorbidities identified were hypertension, depression, diabetes, chronic kidney disease, and hypothyroidism
Furthermore, during the initial encounter, most patients were given systemic therapies (n = 64), in which more than 20 systemic therapies were tried. Health care utilization was examined in 53 patients with at least 6 months of follow-up, with 19 patients (35.8%) reporting hospitalization for GPP symptoms at a median (interquartile range) rate of 0.5 (0.4-1.6) hospitalizations per year.
The median number of dermatology visits reported was 3.2 (2.2-6.1) per year, with a maximum of 18 visits per year of follow-up time. Women were shown to be at a 81% decreased risk of an ED encounter or hospital admission during follow-up in age- and sex-adjusted models (OR, 0.19; 95% CI, 0.04-0.83).
“The results of this case series evaluation support prior findings that GPP is a rare, chronic disease without standard treatment and is associated with continued health care utilization over time,” concluded the researchers. “Further prospective research is necessary to better understand treatment efficacy in patients with GPP.”
Reference
Noe MH, Wan MT, Mostaghimi A, et al. Evaluation of a case series of patients with generalized pustular psoriasis in the United States. JAMA Dermatol. Published online December 8, 2021. doi:10.1001/jamadermatol.2021.4640
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More